A new UK consortium has been established to independently evaluate artificial intelligence technologies in dermatology, with its clinical leaders saying the initiative could help inform AI assurance frameworks internationally as health systems, including Australia’s, grapple with the safe adoption of diagnostic AI.
The British Association of Dermatologists (BAD) launched the Skin and Responsible Artificial Intelligence (SkinRAI) Consortium at its 106th Annual Meeting in Manchester.
The clinically led initiative will assess whether AI tools used in dermatology are safe, effective, equitable, and clinically useful before they are implemented more widely across the NHS.
The launch follows recommendations from the National Commission into the Regulation of AI in Healthcare, which called for trusted datasets, real-world evidence, ongoing evaluation, and post-market monitoring to underpin safe AI adoption.
To read more on this article please click here.
